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Objective: The short-term benefits of bilateral stimulation of the subthalamic nucleus (STN) in patients with
advanced Parkinson’s disease (PD) are well documented, but long-term benefits are still uncertain. The aim of this
study is to evaluate the outcome of 8 years of bilateral STN stimulation to PD patients.
Methods: In this study, 31 consecutive PD patients were treated with bilateral STN stimulation. Their functional
status was measured using the Activities of Daily Living section of the Unified Parkinson’s Disease Rating Scale
(UPDRS-ADL) at drug on (with medication) and drug off (without medication) states preoperatively and at 1, 5, and
8 years postoperatively. In addition, Levodopa equivalent doses and stimulation parameters were also assessed.
Results: After 8 years of STN stimulation, the UPDRS-ADL scores were improved by 4% at drug off status (P > 0.05)
and 22% at drug on status (P < 0.05) compared with baseline; the levodopa daily doses were reduced by 28%
(P < 0.05) compared with baseline; the stimulation voltage and pulse width were not changed, but the stimulation
frequency was decreased remarkably compared with the 5 years of follow-up. Adverse events were observed in 6
patients, including misplacement of the electrode and skin erosion requiring further surgery. All events were
resolved without permanent sequelae. 2 patients died of aspiration pneumonia 6 and 7 years after surgery.
Conclusions: The marked improvement in UPDRS-ADL scores were still observed after 8 years of bilateral STN
stimulation with medication.
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Chronic high-frequency deep brain stimulation (DBS) has
been a standard surgical treatment to the Parkinson’s dis-
ease (PD) patients. The subthalamic nucleus (STN) stimu-
lation can both alleviate the parkinsonian motor disability
and reduce the daily dose of levodopa [1,2]. So far, it has
not been possible to definitively determine whether the ef-
fectiveness of DBS decays over time or if DBS generates
neuroprotective effect [3], since only limited recordings
on the long-term clinical course of the patients with DBS
surgery are available [4,5].
Between 1999 and 2011, 304 levodopa responsive PD pa-
tients were treated with STN stimulation in Ruijin Hos-
pital, Shanghai Jiaotong University School of Medicine.
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reproduction in any medium, provided the oractivities of daily living scores (Unified Parkinson Disease
Rating Scale II (UPDRS-ADL)) of 93% patients showed a
50% improvement after 1 year of STN stimulation, which
were evaluated after an overnight withdrawl of levodopa
(stimulation on and drug off condition). Additionally, the
average levodopa equivalent doses were reduced by 45%
after 1 year of STN stimulation (not published). Herein, we
present the results of functional status, levodopa equivalent
dosages and stimulation parameters obtained from a series
of 31 consecutive PD patients with STN stimulation before
surgery and at 1, 5 and 8 years after surgery.Materials and methods
Patients
During the period of January 2000 and August 2003, 31
consecutive PD patients (22 men and 9 women, mean age
53.5 ± 11.7 years) were operated with bilateral STN stimu-
lation. The selection criteria were: (i) clinically diagnosed
idiopathic PD patients with Hoehn and Yahr scale (stage 2his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toms in response to levodopa treatment [8]. The study
was carried out after the local institutional review board
approval was obtained and all participants provided their
written informed consent. None of the patients was
demented and depressed as determined by neuropsycho-
logical assessment. 2 patients died of aspiration pneumo-
nia 6 and 7 years after surgery.Surgical procedure
The neurosurgical procedure was performed as previously
described [9]. The intended target coordinates were deter-
mined on the basis of 1.5 T magnetic resonance imaging
(MRI), then the electrodes (model 3387–40, 7428,
Medtronic, Minneapolis, MN, USA) were stereotactially
implanted into the bilateral STN under local anesthesia.
Intraoperative macroelectrode stimulation was used in
confirming the target position. At last the electrodes were
connected to the extension wires (7482, Medtronic) and
the programmable pulse generator (IPG) (bilateral Itrel® II,
unilateral Kinetra; Medtronic) was implanted subclavi-
cularly under general anesthesia. IPG programming was
initiated on the following day. Electrical parameters (volt-
age, pulse width, and frequency) were progressively ad-
justed using an electromagnetic programmer (7532, 8840
neurological programmer; Medtronic).Clinical evaluation
The quality of life was assessed with UPDRS-ADL scores
preoperatively (baseline) and at 1, 5 and 8 years postoper-
atively at drug off state after overnight withdrawl of
antiparkinsonian medication and drug on state after the
administration of a single suprathreshold dose of levodopa
(150% of the usual effective dose taken in the morning),
respectively. The percentage improvements of UPDRS-
ADL scores at 1, 5 and 8 years after surgery were calcu-
lated compared with baseline at drug off and drug on
statuses, respectively. The levodopa equivalent dosages
and stimulation parameters were also documented. The
UPDRS-ADL assessments were scored through clinic
interview and telephone interview by a blinded rater (DL).
Anti-parkinsonnian drugs and doses were recorded at
each interview and transformed into levodopa equivalent
daily doses [5]. All the evaluations after surgery were
performed when PD patients were in routine stimulation.Statistical analysis
Data were expressed as mean ± SD. Statistical analysis was
performed by repeated measures analysis of variance
followed by Bonferroni. SPSS (version13.0, SPSS, Chicago,
IL, USA) was used for the statistical analysis. The signifi-
cance levels were set at P < 0.05.Results
Effects of continuous bilateral STN stimulation on the
quality of life of PD patients
Compared with the drug off baseline, the ADL scores
were improved by 58%, 33%, and 4% at 1, 5 and 8 years
postoperatively under stimulation on and drug off status.
Compared with the drug on baseline, the ADL scores were
improved by 69%, 49%, and 22% at 1, 5 and 8 years post-
operatively under stimulation on and drug on status
(Table 1). These findings indicate that with STN stimula-
tion, the quality of life of patients was better than baseline
at 1 and 5 years under drug off condition, and the effect
didn’t remain 8 years. However, the marked improvement
of UPDRS-ADL scores still remained at 8 years postopera-
tively under stimulation on and drug on condition.
The UPDRS-ADL scores appeared more improvement
under STN stimulation and drug treatment than sole
stimulation at 5 and 8 years after surgery, but not at 1
year after surgery.
Medications and stimulation settings
Compared with preoperative condition, the daily dose of
levodopa equivalent was reduced by 53%, 40%, and 28%
at 1, 5 and 8 years after surgery, respectively (Table 1).
Monopolar stimulation with the use of single or double
contacts from the quadripolar electrode was applied in
90% of the patients. Compared with 1 month after sur-
gery, there are remarkable increases of the mean voltage
and pulse width of stimulation at 1, 5 and 8 years, but the
frequency of stimulation showed obvious decrease at 5
and 8 years. Compared with 1 year after surgery, the mean
voltage of stimulation was increased, but the frequency of
stimulation was decreased and the pulse width of stimula-
tion was not changed at 5 and 8 years. Relative to 5 years
after surgery, there were no change in the mean voltage
and pulse width of stimulation, but there was significant de-
crease in the frequency of stimulation at 8 years (Table 2).
Adverse events
2 patients died of aspiration pneumonia due to swallow
disorders 6 and 7 years after surgery. In 4 patients, malpo-
sition of the electrodes was revealed by ineffectiveness of
stimulation and MRI, and the electrodes were adjusted to
alleviate the symptoms. 2 patients had the skin erosion in
the IPG pocket and the stimulators were repositioned.
There was no symptomatic intracerebral hemorrhage hap-
pened in this study.
Discussion
In this study, we provide 8 years of follow-up of PD pa-
tients with bilateral STN stimulation. Our results indicate
that the improvement of functional status in PD patients
by sole STN stimulation was sustained 5 years after sur-
gery; and this effect declined at 8 years after surgery.
Table 1 Activities of daily living scores and levodopa equivalent doses before surgery (baseline) and 1 year, 5 years
and 8 years after surgery and the percentage change compared with baseline
Baseline 1 year 5 years 8 years
UPDRS-ADL scores Drug off 21.5 ± 8.1 9.2 ± 4.3 (58%)* 14.4 ± 6.0 (33%)*#Ω 20.1 ± 8.6 (4%)#ΩΨ
(Improvement percentage) Drug on 8.8 ± 4.3* 6.4 ± 3.0 (69%)* 10.9 ± 5.5 (49%)*ΔΩ 16.7 ± 7.6(22%)*Δ#ΩΨ
LED (Increase percentage) mg/day 967.8 ± 381.3 457.2 ± 283.7 (53%)# 573.0 ± 383.0 (40%)# 669.1 ± 480.69 (28%)#Ω
Values are means (SD).
* p significant compared with drug off condition before surgery.
# p significant compared with drug on condition before surgery.
Δ p significant compared with drug off condition at the same time of follow-up.
Ω p significant compared with corresponding assessment 1 year after surgery.
Ψ p significant compared with corresponding assessment 5 years after surgery.
LED: Levodopa equivalent doses.
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quality of life was still improved remarkably after 8 years
of stimulation and antiparkinsonian medication, further-
more, the levodopa equivalent dosage is still lower than
that used at preoperative status.
As previously reported, axial signs like postural instabil-
ity and gait disorders of the patients showed the most
striking progressive loss of benefits from stimulation over
time [5,10]. These symptoms have great impact on the
quality of life of PD patients, so the decline in DBS benefit
at the 8-year follow-up might be due to the disease pro-
gression of PD [11] and thus suggests that the STN stimu-
lation is lack of remarkable hindrance to the progression
of PD [10].
The daily doses of levodopa were reduced markedly and
the stimulation voltage and pulse width were increased to
improve the patients symptoms within 5 years of stimula-
tion. 5 years later, the aggravation of symptoms can’t be
compensated by the adjustment of the stimulation param-
eters due to the intolerable side effects caused by high
intensity stimulation. The improvement by medication
was still observed since stimulation can ameliorate some
motor complications of medications [12], unlike the ob-
servation of other groups that PD patients showed a re-
markable progressive loss of levodopa responsiveness over
the years [13,14]. In our study, the patients of younger-
onset (53.5 years) and relatively shorter duration (7.86
years) might contain more dopaminergic reactive recep-
tors in striatum, which bring about the consistent respon-
siveness to levodopa over the years, and also resulted in
less surgical complications relative other study [15].Table 2 Stimulation parameters at 1 month, 1 year, 5 years a
Stimulation parameters 1 month 1 year
Amplitude (V) 2.2 ± 0.3 (1.6-2.7) 2.6 ± 0.4 (1.9-3.
Pulse width (μs) 60.0 ± 0.0 (60–60) 75.8 ± 15.2 (60–
Rate (Hz) 163.2 ± 14.2 (130-185) 159.9 ± 13.3 (13
Data presented as mean ± SD (range).
※ p significant compared with 1 month after surgery.
# p significant compared with 1 year after surgery.
△ p significant compared with 5 years after surgery.Compared with 5 years of follow-up, stimulation voltage
and pulse width were not changed at the 8 years of
follow-up, but the stimulation frequency was reduced. At
the beginning of stimulation, high frequency (160-185 Hz)
was applied to control the tremor, one of the most prom-
inent symptoms of PD; after the tremor was finally re-
strained with long-term of stimulation [16], the relative
lower frequency (130-145 Hz) was applied. Additionally,
when some of the patients developed the axial symptoms
like swallow, speech and gait disorders, the stimulation
frequency was reduced (85-115 Hz) further to improve
the balance and speech functions, especially in some
bradykinesia or rigidity dominated patients, which is in
consistent to the recently reported studies [17,18].
Our study has several limitations, including the lack of a
PD group with sole medication therapy and double-
blinded assessments, and the lack of stimulation off as-
sessment since most of PD patients can’t endure the
stimulation wash-out period which means stimulation is
turned off at least 2 hours [12]. Because data of UPDRS
III motor scores of 7 patients at 5 years of follow-up have
not been reached until now, the UPDRS III motor scores
are not reported in this study.
Conclusion
Our findings confirm the continuous improvement in the
functional status of PD patients by 8 years of bilateral
STN stimulation, combined with antiparkinsonian medi-
cation. In our study, the marked efficacy of STN stimula-
tion in meliorating the functional status of parkinsonian
disability results primarily from the strict selection ofnd 8 years of follow-up
5 years 8 years
3)※ 2.7 ± 0.4 (1.9-3.5)※# 2.8 ± 0.4 (2.2-3.6)※#
90)※ 80.8 ± 17.3 (60–120)※ 80.8 ± 17.3 (60–120)※
0–185) 150.1 ± 12.2 (130–160)※# 141.3 ± 14.6 (85-160)※#Δ
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of the medication and IPG programming after surgery by
a multidisciplinary team.
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